BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: In our studies aimed at identifying genetic causes for resistance to tyrosine kinase inhibitors (TKIs) in patients diagnosed with chronic myelogenous leukemia (CML), we discovered a 2,903-bp deletion polymorphism within BIM intron 2 that was strongly associated with this resistance.